ACBP/DBI (E4V8V) XP® Rabbit mAb #40487
- WB
- IHC
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 10 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:500 - 1:2000 |
Storage
Protocol
Specificity / Sensitivity
ACBP/DBI (E4V8V) XP® Rabbit mAb recognizes endogenous levels of total ACBP/DBI protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant human ACBP/DBI protein.
Background
Acyl-CoA-binding protein (ACBP) binds to long-chain acyl-CoA molecules and regulates lipid metabolism. This protein is also known as diazepam-binding inhibitor (DBI) and binds to the benzodiazepine-binding site of the γ-aminobutyric acid (GABA) type A receptor (GABAAR), regulating its activity (1). ACBP/DBI is highly expressed in glioblastoma and promotes glioblastoma growth by providing long-chain acyl-CoA molecules to mitochondria for fatty acid oxidation. Reduced ACBP/DBI expression leads to slower proliferation of glioblastoma (2,3). In addition, ACBP/DBI is a regulator of neural progenitor and stem cell proliferation in adult mouse neurogenic niches (4,5). Studies show that ACBP/DBI modulates embryonic neurogenesis of excitatory and inhibitory neurons through GABA signaling (6).
- Bravo-San Pedro, J.M. et al. (2019) Cell Metab 30, 754-767.e9.
- Duman, C. et al. (2019) Cell Metab 30, 274-289.e5.
- Bi, J. and Mischel, P.S. (2019) Cell Metab 30, 229-230.
- Alfonso, J. et al. (2012) Cell Stem Cell 10, 76-87.
- Dumitru, I. et al. (2017) Neuron 94, 125-137.e5.
- Everlien, I. et al. (2022) Neuron 110, 3139-3153.e6.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.